FDA grants orphan-drug status to Erytech's leukemia drug

01/27/2010 | American City Business Journals

Graspa, Erytech Pharma's drug candidate for acute lymphoblastic leukemia, received orphan-drug designation from the FDA. The drug is a novel L-asparaginase formulation packed in red blood cells to make it safer. Erytech is considering starting clinical trials of the drug in the U.S., CEO Yann Godfrin said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI